Last Updated 16\/09\/26<\/p>\n\n\n\n
SPARVASC (SPARsentan in VASCulitis)<\/strong><\/p>\n\n\n\n Cohort study examining endothelin and angiotensin system blockade in ANCA vasculitis.<\/p>\n\n\n\n Recruiting health board: NHS Lothian.<\/p>\n\n\n\n Contact: Neeraj Dhaun (Bean); bean.dhaun@ed.ac.uk<\/a> <\/p>\n\n\n\n MEMRI-Kidney (Manganese-enhanced MRI in Kidney Disease)<\/strong><\/p>\n\n\n\n Identifying patients with acute kidney injury due to ANCA vasculitis at-risk of chronic kidney and cardiovascular disease.<\/p>\n\n\n\n Recruiting health board: NHS Lothian<\/p>\n\n\n\n Contact: Neeraj Dhaun (Bean); bean.dhaun@ed.ac.uk<\/a> <\/p>\n\n\n\n OCTANE (Optical Coherence Tomography and NEphropathy)<\/strong><\/p>\n\n\n\n Imaging study using optical coherence tomography (OCT) to assess changes in retinal metrics in patients with ANCA-associated vasculitis compared to healthy controls. Serial scans will explore whether metrics are modifiable over time in response to treatment.<\/p>\n\n\n\n Recruiting health board: NHS Lothian<\/p>\n\n\n\n Contact: Neeraj Dhaun (Bean); bean.dhaun@ed.ac.uk<\/a> <\/p>\n\n\n\n Exploring the role of fibroblasts in disease relapse in Giant Cell Arteritis.<\/strong><\/p>\n\n\n\n Cohort study using transcriptomic, immunohistochemical and in vitro methods to establish the role of fibroblasts in GCA relapse.<\/p>\n\n\n\n Recruiting health board (s): Grampian<\/p>\n\n\n\n PI: Maira Karabayas<\/p>\n\n\n\n Contact details: maira.karabayas@abdn.ac.uk<\/a><\/p>\n\n\n\n The role of Siglec-9 in ANCA associated vasculitis.<\/strong><\/p>\n\n\n\n Translational study aimed at exploring novel mechanisms involving siglecs in ANCA vasculitis. Recruiting health board: NHS Grampian. Contact: dana.kidder@nhs.scot<\/a><\/p>\n\n\n\n Fast Field Cycling imaging as a novel non-invasive approach to evaluate kidney health and disease: a proof-of-concept study. <\/p>\n\n\n\n Recruiting health board: NHS Grampian.<\/p>\n\n\n\n Contact: dana.kidder@nhs.scot<\/a><\/p>\n\n\n\n RACEMATE trial.<\/strong><\/p>\n\n\n\n A Randomised Placebo Controlled Trial \u2013 to Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis with Polyangiitis.<\/p>\n\n\n\n Recruiting board: NHS Grampian<\/p>\n\n\n\n Contact: david.miller@nhs.scot<\/a><\/p>\n\n\n\n AVACOSTAR<\/strong><\/p>\n\n\n\n Observational study to evaluate safety outcomes for Avacopan in ANCA associated vasculitis.<\/p>\n\n\n\n Recruiting board: NHS GG&C<\/p>\n\n\n\n Contact: neil.basu@glasgow.ac.uk<\/a><\/p>\n\n\n\n TARDIS – Tar<\/strong>get Identification for Drug Dis<\/strong>covery in Giant Cell Arteritis<\/p>\n\n\n\n Recruiting board: NHS GG&C<\/p>\n\n\n\n Contact: neil.basu@glasgow.ac.uk<\/a><\/p>\n\n\n\n PANDA-VASC<\/strong><\/p>\n\n\n\n Imaging study using PET imaging to investigate patterns of vascular inflammation and compare PET findings between AAV and other systemic autoimmune diseases. Serial scans will explore whether metrics are modifiable over time in response to treatment. <\/p>\n\n\n\n Recruiting health board: NHS Lothian<\/p>\n\n\n\n Contact: Neeraj Dhaun (Bean);\u00a0bean.dhaun@ed.ac.uk<\/a><\/p>\n\n\n\n RITUXIMAP<\/strong> <\/p>\n\n\n\n Imaging study using PET imaging with radiolabeled rituximab to investigate patterns of CD20+ uptake and vascular inflammation in patients with LV-GCA. Repeat scans will be performed to assess response to standard of care treatment.<\/p>\n\n\n\n Recruiting health board: NHS Lothian<\/p>\n\n\n\n Contact: Neil Basu;\u00a0neil.basu@glasgow.ac.uk<\/a>\u00a0:Neeraj Dhaun (Bean);\u00a0bean.dhaun@ed.ac.uk<\/a>\u00a0<\/p>\n\n\n\n DERAIL-LVV<\/strong> (Dapagliflozin and endothelial receptor antagonism in large vessel vasculitis) <\/p>\n\n\n\n Prospective clinical study evaluating the use of the endothelin receptor antagonist bosentan in combination with the SGLT2i dapagliflozin in patients with large vessel vasculitis in remission. <\/p>\n\n\n\n Recruiting health board: NHS Lothian<\/p>\n\n\n\n